<< Medical schools change curriculum to adapt to different policies, care standards | Strategic analysis of the US cardiac rhythm management devices market >>

Roxane Laboratories receives ANDA approval for Perindopril Erbumine Tablets

Published on November 11, 2009 at 12:32 AM · No Comments

Roxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA) for Perindopril Erbumine Tablets, 2mg, 4mg and 8mg by the U.S. Food and Drug Administration. The product is available in bottles of 100 for immediate shipment to wholesalers and pharmacies nationwide.

Roxane Laboratories' Perindopril Erbumine Tablets are AB rated to ACEON® (perindopril erbumine) tablets. Annual sales of ACEON® are approximately $24.1 Million.

SOURCE Roxane Laboratories, Inc.

062a454e-10fa-4342-8cc2-0f73a69445af|0|.0

Posted in: Pharmaceutical News

Tags: New Drug Application, Perindopril

Roxane Laboratories announces FDA approval of Imipramine Pamoate Capsules ANDARoxane Laboratories, Inc. announced today the approval of its Abbreviated New Drug Application (ANDA...
Sinobiopharma announces Chinese approval of PerindoprilSinobiopharma, Inc. has announced that it has received approval from the Chinese State Food and Drug...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.